Disclosure
Anthony Pompliano has said on The Pomp Podcast that Investor Health, which offers clinician-prescribed protocols that include GLP-1 medications, is "a company that we've built." Novo Nordisk's Ozempic and Wegovy are GLP-1 drugs.
The short answer: Novo Nordisk (NYSE: NVO) is the Danish drugmaker behind Ozempic and Wegovy, two of the best-known GLP-1 drugs for diabetes and weight loss. It was founded in 1923, and Maziar Mike Doustdar is CEO. It was worth about $172 billion as of October 23, 2026, down about 28% over the prior year.
A company profile from The Pomp Podcast, hosted by Anthony Pompliano. Last updated: October 25, 2026.
Key takeaways
Novo Nordisk is a Danish drugmaker founded in 1923 that makes the GLP-1 drugs Ozempic and Wegovy.
Maziar Mike Doustdar is CEO.
It was worth about $172.38 billion on October 23, 2026, down about 28% over the prior year.
What is Novo Nordisk?
Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark, according to its company profile. Its biggest products are semaglutide drugs sold as Ozempic for type 2 diabetes and Wegovy for weight loss, now including a Wegovy pill.
How big is Novo Nordisk?
Novo Nordisk's market value was about $172.38 billion at the close on October 23, 2026, according to StockAnalysis. That was down about 28% from a year earlier. Its U.S. rival in the same drug class, Eli Lilly, was worth about $1.14 trillion that day, according to StockAnalysis. See What Is Eli Lilly?.
How did Novo Nordisk do last quarter?
In its second-quarter 2026 report, Novo Nordisk said:
Adjusted sales rose 7% at constant exchange rates, and reported sales rose 3%.
Adjusted Ozempic sales were about DKK 31.4 billion in the quarter, and Wegovy pill sales were about DKK 3.2 billion.
U.S. weekly prescriptions for the Wegovy pill topped 265,000 in the week ending July 17.
The Wegovy pill won European approval in July.
It raised its 2026 outlook and now expects adjusted sales and adjusted operating profit to range from flat to down 6% at constant exchange rates.
The company also said it was saving money from a company-wide restructuring it announced in the third quarter of 2025. Novo Nordisk will report results for the first nine months of 2026 on November 4, 2026, according to its investor site.
What did The Pomp Podcast say about Novo Nordisk?
Novo's drugs came up on the October 24, 2026 episode with Jordi Visser, "Will Bitcoin Survive Quantum Computing? | Jordi Visser". Quotes below are from the episode, with timestamps.
"Ozempic has helped a lot of people in the country"
Later, explaining why Eli Lilly is his biggest long position, he said:
"You've made a lot of money if you've just sat in Eli Lilly purely based on Ozempic"
One correction: Ozempic is made by Novo Nordisk, not Eli Lilly. Lilly's competing drugs are Mounjaro and Zepbound. His larger point was that GLP-1 drugs have made Lilly very profitable. See why Jordi thinks Eli Lilly could become the biggest company.
Every Pomp Podcast episode that discussed Novo Nordisk and Ozempic
Novo Nordisk and Ozempic came up in 1 recent episode of The Pomp Podcast. Each link opens the YouTube video at that moment.
Oct 24, 2026: Will Bitcoin Survive Quantum Computing? | Jordi Visser. Jordi Visser talked about GLP-1 drugs and Eli Lilly. Timestamps: 46:52 (Ozempic), 50:18 (Eli Lilly and GLP-1s).
Watch or listen to the episode
Will Bitcoin Survive Quantum Computing? | Jordi Visser, released October 24, 2026. The Ozempic comments are at 47:02.
Opinions from guests on The Pomp Podcast are their own. Nothing on this page is a recommendation to buy or sell any security.
FROM THE HOST
Put AI to work on your own financial questions.
Silvia is a personal AI CFO, built by investors, for investors. It answers questions about your cash flow, investments and goals using your own financial context, and organizes the details so you can review them. Access is read-only.
Disclosure: Anthony Pompliano is Chairman and CEO of Silvia, Inc. For educational purposes only; not financial advice.
Where can I follow Novo Nordisk?
Novo Nordisk posts results and its financial calendar on its investor site.
Subscribe to The Pomp Podcast on YouTube, Apple Podcasts or Spotify.
Frequently asked questions
What is Novo Nordisk?
Novo Nordisk is a Danish drugmaker founded in 1923. It makes Ozempic and Wegovy, two of the best-known GLP-1 drugs.
Who makes Ozempic?
Novo Nordisk. Eli Lilly makes competing drugs called Mounjaro and Zepbound.
Who is the CEO of Novo Nordisk?
Maziar Mike Doustdar.
How much is Novo Nordisk worth?
About $172.38 billion at the October 23, 2026 close, down about 28% over the prior year, according to StockAnalysis.
When does Novo Nordisk report earnings?
It will report results for the first nine months of 2026 on November 4, 2026.
Sources
Last updated: October 25, 2026
Anthony Pompliano is an entrepreneur, investor, and author who serves as Chairman and CEO of Silvia, Inc (SVIA) and invests through Pomp Investments. He is the host of The Pomp Podcast, where he interviews founders, investors and economists about bitcoin, markets, AI and the economy.
Follow Pomp on X.
Subscribe
Get notified for every new Pomp Podcast episode.
Subscribe for free to learn alongside Anthony Pompliano.
This profile is for informational purposes only and reflects reporting available as of October 25, 2026, plus opinions shared on The Pomp Podcast. It is not investment advice. Do your own research before making any investment decision.
